Peficitinib hydrobromide to treat rheumatoid arthritis.
-
S.R. Gutiérrez-Ureña [1] ; E.L. Amaya-Cabrera [1] ; J.F. Uribe-Martínez [1] ; M.E. Ventura-Valenzuela [1] ; C. Rosal-Arteaga [1] ; G.E. Martínez-Bonilla [1] ; V. González-Díaz [1] ; O. Almengor-Montenegro [1] ; S. Cerpa-Cruz [1]
-
[1] Rheumatology Department, Hospital Civil de Guadalajara FAA, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 56, Nº. 8, 2020, págs. 505-514
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Peficitinib hydrobromide is a small Janus kinase inhibitor (JAK1, JAK2, JAK3 and TYK2) molecule for the treatment of rheumatoid arthritis (RA). Phase II and phase III clinical trials and extension studies with different doses have been conducted to assess the drug’s efficacy and safety with substantially improved outcomes observed in RA. This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX. The findings from studies of this new JAK inhibitor have shown that, both in monotherapy as well as in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), it has efficacy, safety and tolerability in RA patients.
